Evidence map›Paper›PMID 42708906›Full record

ReviewACS nano2026

MXene Chemistries for Biomedicine: On-Body, In-Body, and Beyond.

Damla Alkaya, Roberta Cagliani, Gokce Yagmur Summak, Linda Giro, Omur Besbinar, Maha Alhosani, Maksym Pogorielov, Mehak Gupta, Sanjiv Dhingra, Marco Orecchioni and 9 more

Abstract readReview
In one paragraph

Review in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Damla AlkayaIntegrated Technologies Research Center (BÜTAM), Ankara University, 06790Ankara, Türkiye.ORCID 0000-0002-7638-4907
Roberta CaglianiDepartment of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.
Gokce Yagmur SummakIntegrated Technologies Research Center (BÜTAM), Ankara University, 06790Ankara, Türkiye.
Linda GiroDepartment of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.
Omur BesbinarIntegrated Technologies Research Center (BÜTAM), Ankara University, 06790Ankara, Türkiye.
Maha AlhosaniDepartment of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.ORCID 0009-0006-1626-7174
Maksym PogorielovInstitute of Atomic Physics and Spectroscopy, Faculty of Science and Technology, University of Latvia, RigaLV-1004, Latvia.
Mehak GuptaDepartment of Physiology and Pathophysiology, University of Manitoba, Winnipeg, ManitobaR3E 0J9, Canada.
Sanjiv DhingraDepartment of Physiology and Pathophysiology, University of Manitoba, Winnipeg, ManitobaR3E 0J9, Canada.ORCID 0000-0002-2664-7633
Marco OrecchioniImmunology Center of Georgia, Augusta University, Augusta, Georgia30912, United States.
Flavia VitaleDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania19104, United States.
Giacomo ChessaDepartment of Biomedical Engineering and Biotechnology, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.
Valentina PalmieriInstitute for Complex Systems CNR Consiglio Nazionale delle Ricerche, 00185Rome, Italy.
Benjamin ChaconA.J. Drexel Nanomaterials Institute and Department of Materials Science and Engineering, Drexel University, Philadelphia, Pennsylvania19104, United States.
Yury GogotsiBiomedical Research Centre, Sumy State University, Sumy40007, Ukraine.ORCID 0000-0001-9423-4032
Anna-Maria PappaDepartment of Biomedical Engineering and Biotechnology, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.ORCID 0000-0002-7980-4073
Laura FuscoDepartment of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.
Acelya YilmazerIntegrated Technologies Research Center (BÜTAM), Ankara University, 06790Ankara, Türkiye.ORCID 0000-0003-2712-7450
Lucia Gemma DeloguDepartment of Biological Sciences, Khalifa University of Science and Technology, Abu Dhabi127788, United Arab Emirates.ORCID 0000-0002-2329-7260

Funding

Horizon 2020 European Commission (EC) 101199993HORIZON EUROPE Marie Sklodowska-Curie Actions 101086184Khalifa University of Science, Technology and Research KU-INT-FSU-2024-8474000719Khalifa University of Science, Technology and Research KU-INT-IRNE-2025-8471000005Ministero dell?Istruzione, dell?Universit? e della Ricerca 101199993 CUP C93C25004760006Ministero dell?Istruzione, dell?Universit? e della Ricerca 202274SLX8Ministero dell?Istruzione, dell?Universit? e della Ricerca CUP C53D23002300001NextGenerationEU NAResearch and Innovation Center for Graphene and 2D Materials, Khalifa University of Science and Technology OC077
6 · The paper itself

Abstract

MXenes, a rapidly expanding family of two-dimensional transition-metal carbides, nitrides, and carbonitrides, have gained considerable attention as highly versatile nanomaterials for biomedical applications owing to their high electrical conductivity, chemically tunable surfaces, mixed ionic-electronic transport, and controllable redox activity. This review provides a structured overview of MXene-based biomedical technologies, organized by their functional interaction with the human body. We first examine on-body applications, highlighting MXene-enabled wearable, epidermal, and implantable bioelectronics. We then discuss in-body applications, including regenerative medicine, advanced cancer therapies, and antimicrobial strategies, emphasizing how MXene chemistry regulates biological interactions and therapeutic performance. Finally, we address applications outside the body, such as biosensing and diagnostic platforms, where MXenes enhance sensitivity, signal transduction, and imaging capabilities. Beyond summarizing recent advances, this review critically analyzes current gaps in knowledge, including long-term biocompatibility, degradation pathways, immune interactions, and structure-activity relationships, which currently limit clinical translation. We conclude by outlining key future directions, including sustainable synthesis, oxidation-resistant and fluorine-free MXenes, and the integration of artificial intelligence to accelerate materials discovery and application-specific design. Together, these insights position MXenes as chemistry-programmable nanoplatforms with strong potential to bridge on-body, in-body, and outside-the-body biomedical technologies.

Indexed as

Biocompatible MaterialsNanostructuresAnimalsBiosensing TechniquesHumansNitritesTransition ElementsBiocompatible MaterialsMXeneNitritesTransition Elementsbioelectronicsbiosensingcancer nanotherapyimmunomodulationMXenesregenerative medicinesustainable nanomaterialstwo-dimensional materials

Identifiers

PMID42708906
PMCPMC13564987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.